The gene-editing track has gained another major boost: Yaotang Biotech’s Series C round is nearing 500 million yuan, with Zhengxinggu leading the investment—this is a truly bold move.

View Original
MarsBitNews
Yao Tang Biotechnology completes nearly 500 million RMB Series C funding
Mars Finance News: On May 29, YolTech Therapeutics announced the completion of nearly RMB 500 million in Series C financing. This round was led by ZhengxinGu Capital, with participation from well-known institutions including Shanghai Guotou XianDao, MinjinTou, and Deyue Investment. Existing shareholders Xianfeng Qiyun, Yuanyi Investment, and Tianchuang Capital also increased their stakes and followed with additional investment. (Venture Capitalist CLUB)
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned